4. We Have a Solid Industry Base, but…
2.8.2016 4Source: FiHTA, 2015
5. Fundamental Disconnect
• Pools of investment capital are forming
around academic science
• Money needed to get those discoveries into
and through the clinic continues to lag
• U.S. investors are beginning to close the gap –
but only for companies with global ambition
2.8.2016 5Source: Bioequity Europe 2016, Fishburn and Schaeffer
9. Startups are not successful simply because
they are founded with great ideas.
What's important is the execution and
putting in place the right people and
resources early on - to shape the
core values and mission of the enterprise.
2.8.2016 9
10. Share of Global Capital –
EU is Left Behind
2.8.2016 10Source: BCIQ, BioCentury Online Intelligence
13. Questions Needing Answers
• What’s needed in Europe (Finland) to get more U.S.
Investor representation?
– Local lead investors
• The investors close to you are more likely to
invest than those farther away
– Help startups with DD process / documentation
2.8.2016 13
14. Questions Needing Answers
• What’s driving the influx of money for translation?
– Genuine, well drafted IP
– Success
– Location
2.8.2016 14
15. Questions Needing Answers
• What will it take beyond the money to turn
scientific discoveries into products for patients?
– TEAM
– Execution
– Commitment / Passion
2.8.2016 15
16. Additional Hallmarks of Ambition
• Serial entrepreneurs with success
• Pharma experience
• U.S. Office – go where the market is
• Cornerstone European (Finnish) VC
2.8.2016 16